Stenger Family Office LLC Buys Shares of 14,921 Johnson & Johnson (NYSE:JNJ)

Stenger Family Office LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 14,921 shares of the company’s stock, valued at approximately $2,158,000.

Several other institutional investors have also modified their holdings of the business. NFJ Investment Group LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $10,774,000. Finward Bancorp acquired a new position in Johnson & Johnson in the 4th quarter worth $1,554,000. United Capital Financial Advisors LLC increased its holdings in Johnson & Johnson by 10.1% during the 4th quarter. United Capital Financial Advisors LLC now owns 291,841 shares of the company’s stock worth $42,206,000 after purchasing an additional 26,674 shares in the last quarter. Delaney Dennis R lifted its holdings in shares of Johnson & Johnson by 1.9% in the fourth quarter. Delaney Dennis R now owns 40,032 shares of the company’s stock valued at $5,789,000 after purchasing an additional 730 shares in the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of Johnson & Johnson by 1.3% during the fourth quarter. Gabelli Funds LLC now owns 195,485 shares of the company’s stock worth $28,271,000 after buying an additional 2,450 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE JNJ opened at $153.66 on Wednesday. The stock’s fifty day moving average is $159.39 and its 200 day moving average is $155.10. The stock has a market capitalization of $370.29 billion, a P/E ratio of 23.11, a PEG ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Raymond James dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $171.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.